Targets › KLB
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine.
Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. (UniProt, Q86Z14)
Open in Phaseline: the race on KLB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biohaven Therapeutics | Taldefgrobep Alfa FGF21 receptor agonist (FGF21 analog) | FGFR1, FGFR4, KLB | Phase 2 | Obesity | – |
Obesity (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.